Novartis & Lundbeck: Significance of Drug Transporters Now and in the Future

Add bookmark

The Clinically Relevant Drug Transporters Conference has been a major DMPK meeting point in Europe for 5 years now. In preparation for this year’s 5th annual meeting in Berlin, we asked Dr. Lassina Badolo - Principal Scientist, Discovery DMPK at H. Lundbeck A/S, and Dr. Imad Hanna at Senior Fellow DMPK, Novartis Pharmaceuticals the following questions in an attempt to re-assess the significance of Transporters now and in the future: Are drug transporters less of a priority for co...
To continue reading this story get free access

RECOMMENDED